Having trouble accessing articles? Reset your cache.

Zafgen speaks

Beloranib's prospects remain unclear despite Zafgen's conference call

The prospects for obesity candidate beloranib are not any clearer, even after Zafgen Inc. broke its week-long virtual silence with a Friday conference call to explain a partial clinical hold to investors. After a week fueled by rumors and speculation, initially triggered by a steep stock decline on no news, Zafgen is down 70% and trading barely above cash.

On Monday, the stock plummeted $12.25 (36%) to $22.15 on heavy volume amid general media reports that Zafgen had pulled out of non-road show investor meetings. As speculation mounted, and with no word from the company, the shares shed an additional $6.40 (29%) to $15.75 on Tuesday, again on heavy volume.


Read the full 1114 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers